The following is a summary of the Inhibikase Therapeutics, Inc. (IKT) Q1 2024 Earnings Call Transcript:

Financial Performance:

• Inhibikase Therapeutics indicated a net loss for Q1 2024 of $4.6 million, or $0.73 per share, a minor increase from a net loss of $4.5 million, or $0.98 per share from the same period in 2023.

• As of the end of Q1 2024, the company holds $9.7 million in cash and cash equivalents, expected to sustain operations till November 2024.

Business Progress:

• Significant strides are being achieved in the Phase 2, 201 trial for Risvodetinib or Risvo in Parkinson's disease, with patient enrollment to conclude in June and top-line data slated for H2 2024.

• Constructive engagements with two FDA divisions for their Imatinib project program, IkT-001Pro, aiming at exploring potential opportunities in pulmonary arterial hypertension and gastroenterological and hematological cancers.

• An innovative antibody targeting a key marker of alpha-synuclein pathology in Parkinson's disease is under development, which could potentially improve pathology tracking and elimination.

• Following a pre-IND meeting with the FDA, the potential application of IkT-001Pro as a PAH treatment was discussed, highlighting potential approval pathways and the possibility of receiving novel chemical entity status for the drug in treating PAH.

More details: Inhibikase Therapeutics IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.